ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Agenus Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action pertains to securities purchased between January 23, 2023, and July 17, 2024, with a lead plaintiff deadline set for November 5, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [4] Group 2: Allegations Against Agenus - The lawsuit alleges that Agenus made false and misleading statements regarding the effectiveness of its combination therapy involving botensilimab and balstilimab [3] - It is claimed that the clinical results and regulatory prospects of these therapies were overstated, leading to materially false public statements [3] - The lawsuit asserts that investors suffered damages when the true details about the therapies were revealed [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [2] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [2] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [2]